A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic Genotype 3 HCV Infection and Cirrhosis
A study for patients with Chronic Genotype 3 HCV Infection and Cirrhosis using study drugs Sofosbuvir, Velpatasvir and GS-9857
Sponsor: Gilead Sciences, Inc
Enrolling: Male and Female Patients
IRB Number: AAAQ4900
Contact: Theresa Lukose: 212-305-6758 / tt2103@cumc.columbia.edu
Additional Study Information: This study will compare two experimental drugs, named Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination (SOF/VEL/GS-9857 FDC) and Sofosbuvir/Velpatasvir (SOF/VEL) FDC for the treatment ofchronic genotype 3 hepatitis C virus (HCV) infection in patients who have cirrhosis, or scarring of the liver. The purpose of this study is to determine the efficacy, safety, and tolerability of SOF/VEL/GS-9857 in comparison to SOF/VEL in patients infected with chronic genotype 3 HCV infection and cirrhosis. Information about any side effects that may occur will also be collected.
This study is closed
Elizabeth Verna, MD
Do You Qualify?
Have you been diagnosed with Chronic HCV Infection and Cirrhosis? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Theresa Lukose